Moonlighting newborn screening markers

the incidental discovery of a second-tier test for Pompe disease

Silvia Tortorelli, Jason S. Eckerman, Joseph J. Orsini, Colleen Stevens, Jeremy Hart, Patricia L. Hall, John J. Alexander, Dimitar Gavrilov, Devin Oglesbee, Kimiyo Raymond, Dietrich Matern, Piero Rinaldo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To describe a novel biochemical marker in dried blood spots suitable to improve the specificity of newborn screening for Pompe disease. Methods: The new marker is a ratio calculated between the creatine/creatinine (Cre/Crn) ratio as the numerator and the activity of acid α-glucosidase (GAA) as the denominator. Using Collaborative Laboratory Integrated Reports (CLIR), the new marker was incorporated in a dual scatter plot that can achieve almost complete segregation between Pompe disease and false-positive cases. Results: The (Cre/Crn)/GAA ratio was measured in residual dried blood spots of five Pompe cases and was found to be elevated (range 4.41–13.26; 99%ile of neonatal controls: 1.10). Verification was by analysis of 39 blinded specimens that included 10 controls, 24 samples with a definitive classification (16 Pompe, 8 false positives), and 5 with genotypes of uncertain significance. The CLIR tool showed 100% concordance of classification for the 24 known cases. Of the remaining five cases, three p.V222M homozygotes, a benign variant, were classified by CLIR as false positives; two with genotypes of unknown significance, one likely informative, were categorized as Pompe disease. Conclusion: The CLIR tool inclusive of the new ratio could have prevented at least 12 of 13 (92%) false-positive outcomes.

Original languageEnglish (US)
Pages (from-to)840-846
Number of pages7
JournalGenetics in Medicine
Volume20
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Glycogen Storage Disease Type II
Incidental Findings
Creatine
Creatinine
Genotype
Glucosidases
Homozygote
Biomarkers
Acids

Keywords

  • Collaborative Laboratory Integrated Reports
  • creatine
  • newborn screening
  • Pompe disease
  • second-tier test

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Tortorelli, S., Eckerman, J. S., Orsini, J. J., Stevens, C., Hart, J., Hall, P. L., ... Rinaldo, P. (2018). Moonlighting newborn screening markers: the incidental discovery of a second-tier test for Pompe disease. Genetics in Medicine, 20(8), 840-846. https://doi.org/10.1038/gim.2017.190

Moonlighting newborn screening markers : the incidental discovery of a second-tier test for Pompe disease. / Tortorelli, Silvia; Eckerman, Jason S.; Orsini, Joseph J.; Stevens, Colleen; Hart, Jeremy; Hall, Patricia L.; Alexander, John J.; Gavrilov, Dimitar; Oglesbee, Devin; Raymond, Kimiyo; Matern, Dietrich; Rinaldo, Piero.

In: Genetics in Medicine, Vol. 20, No. 8, 01.08.2018, p. 840-846.

Research output: Contribution to journalArticle

Tortorelli, S, Eckerman, JS, Orsini, JJ, Stevens, C, Hart, J, Hall, PL, Alexander, JJ, Gavrilov, D, Oglesbee, D, Raymond, K, Matern, D & Rinaldo, P 2018, 'Moonlighting newborn screening markers: the incidental discovery of a second-tier test for Pompe disease', Genetics in Medicine, vol. 20, no. 8, pp. 840-846. https://doi.org/10.1038/gim.2017.190
Tortorelli, Silvia ; Eckerman, Jason S. ; Orsini, Joseph J. ; Stevens, Colleen ; Hart, Jeremy ; Hall, Patricia L. ; Alexander, John J. ; Gavrilov, Dimitar ; Oglesbee, Devin ; Raymond, Kimiyo ; Matern, Dietrich ; Rinaldo, Piero. / Moonlighting newborn screening markers : the incidental discovery of a second-tier test for Pompe disease. In: Genetics in Medicine. 2018 ; Vol. 20, No. 8. pp. 840-846.
@article{ba4dddd558764176b555ed7f4acca711,
title = "Moonlighting newborn screening markers: the incidental discovery of a second-tier test for Pompe disease",
abstract = "Purpose: To describe a novel biochemical marker in dried blood spots suitable to improve the specificity of newborn screening for Pompe disease. Methods: The new marker is a ratio calculated between the creatine/creatinine (Cre/Crn) ratio as the numerator and the activity of acid α-glucosidase (GAA) as the denominator. Using Collaborative Laboratory Integrated Reports (CLIR), the new marker was incorporated in a dual scatter plot that can achieve almost complete segregation between Pompe disease and false-positive cases. Results: The (Cre/Crn)/GAA ratio was measured in residual dried blood spots of five Pompe cases and was found to be elevated (range 4.41–13.26; 99{\%}ile of neonatal controls: 1.10). Verification was by analysis of 39 blinded specimens that included 10 controls, 24 samples with a definitive classification (16 Pompe, 8 false positives), and 5 with genotypes of uncertain significance. The CLIR tool showed 100{\%} concordance of classification for the 24 known cases. Of the remaining five cases, three p.V222M homozygotes, a benign variant, were classified by CLIR as false positives; two with genotypes of unknown significance, one likely informative, were categorized as Pompe disease. Conclusion: The CLIR tool inclusive of the new ratio could have prevented at least 12 of 13 (92{\%}) false-positive outcomes.",
keywords = "Collaborative Laboratory Integrated Reports, creatine, newborn screening, Pompe disease, second-tier test",
author = "Silvia Tortorelli and Eckerman, {Jason S.} and Orsini, {Joseph J.} and Colleen Stevens and Jeremy Hart and Hall, {Patricia L.} and Alexander, {John J.} and Dimitar Gavrilov and Devin Oglesbee and Kimiyo Raymond and Dietrich Matern and Piero Rinaldo",
year = "2018",
month = "8",
day = "1",
doi = "10.1038/gim.2017.190",
language = "English (US)",
volume = "20",
pages = "840--846",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Moonlighting newborn screening markers

T2 - the incidental discovery of a second-tier test for Pompe disease

AU - Tortorelli, Silvia

AU - Eckerman, Jason S.

AU - Orsini, Joseph J.

AU - Stevens, Colleen

AU - Hart, Jeremy

AU - Hall, Patricia L.

AU - Alexander, John J.

AU - Gavrilov, Dimitar

AU - Oglesbee, Devin

AU - Raymond, Kimiyo

AU - Matern, Dietrich

AU - Rinaldo, Piero

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Purpose: To describe a novel biochemical marker in dried blood spots suitable to improve the specificity of newborn screening for Pompe disease. Methods: The new marker is a ratio calculated between the creatine/creatinine (Cre/Crn) ratio as the numerator and the activity of acid α-glucosidase (GAA) as the denominator. Using Collaborative Laboratory Integrated Reports (CLIR), the new marker was incorporated in a dual scatter plot that can achieve almost complete segregation between Pompe disease and false-positive cases. Results: The (Cre/Crn)/GAA ratio was measured in residual dried blood spots of five Pompe cases and was found to be elevated (range 4.41–13.26; 99%ile of neonatal controls: 1.10). Verification was by analysis of 39 blinded specimens that included 10 controls, 24 samples with a definitive classification (16 Pompe, 8 false positives), and 5 with genotypes of uncertain significance. The CLIR tool showed 100% concordance of classification for the 24 known cases. Of the remaining five cases, three p.V222M homozygotes, a benign variant, were classified by CLIR as false positives; two with genotypes of unknown significance, one likely informative, were categorized as Pompe disease. Conclusion: The CLIR tool inclusive of the new ratio could have prevented at least 12 of 13 (92%) false-positive outcomes.

AB - Purpose: To describe a novel biochemical marker in dried blood spots suitable to improve the specificity of newborn screening for Pompe disease. Methods: The new marker is a ratio calculated between the creatine/creatinine (Cre/Crn) ratio as the numerator and the activity of acid α-glucosidase (GAA) as the denominator. Using Collaborative Laboratory Integrated Reports (CLIR), the new marker was incorporated in a dual scatter plot that can achieve almost complete segregation between Pompe disease and false-positive cases. Results: The (Cre/Crn)/GAA ratio was measured in residual dried blood spots of five Pompe cases and was found to be elevated (range 4.41–13.26; 99%ile of neonatal controls: 1.10). Verification was by analysis of 39 blinded specimens that included 10 controls, 24 samples with a definitive classification (16 Pompe, 8 false positives), and 5 with genotypes of uncertain significance. The CLIR tool showed 100% concordance of classification for the 24 known cases. Of the remaining five cases, three p.V222M homozygotes, a benign variant, were classified by CLIR as false positives; two with genotypes of unknown significance, one likely informative, were categorized as Pompe disease. Conclusion: The CLIR tool inclusive of the new ratio could have prevented at least 12 of 13 (92%) false-positive outcomes.

KW - Collaborative Laboratory Integrated Reports

KW - creatine

KW - newborn screening

KW - Pompe disease

KW - second-tier test

UR - http://www.scopus.com/inward/record.url?scp=85052738522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052738522&partnerID=8YFLogxK

U2 - 10.1038/gim.2017.190

DO - 10.1038/gim.2017.190

M3 - Article

VL - 20

SP - 840

EP - 846

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 8

ER -